OpenAlex
PricingAboutJobs
Log inGet started
Work

Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1

HTML

Year: 2012
Type: review
Source: Expert Opinion on Drug Discovery
DOI: 10.1517/17460441.2013.741580
Authors: David G Parkes, Kenneth F Mace, Michael E Trautmann
Institution: Eli Lilly (United States)
Language: English

Topic: Diabetes Treatment and Management
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: exenatide, GLP-1 receptor agonists, exendin-4, type 2 diabetes, incretins, Gila monster, glucose-dependent insulin secretion, glucagon suppression, gastric emptying, satiety, beta-cell function, weight loss, pharmacokinetics, toxicology, cardiometabolic effects, hypoglycemia risk, peptide therapeutics
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2059228484
FWCI: 1.015
Cites: 126
Cited by: 123
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security